SEPN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Septerna Inc (SEPN) does not present a strong buy opportunity for a beginner investor with a long-term strategy at this time. Despite positive analyst ratings and a bullish technical setup, the company's financial performance shows significant losses, and there are no strong catalysts or trading signals to justify immediate action.
The technical indicators show a bullish moving average setup (SMA_5 > SMA_20 > SMA_200) and a positive MACD histogram of 0.222, suggesting upward momentum. However, the RSI of 45.738 is neutral, and the stock is trading near its pivot point of 25.079, indicating limited immediate upside potential.
The company's revenue growth in Q4 2025 was significant, up 11276.42% YoY.
The company's net income and EPS have significantly declined (-48.05% and -61.90% YoY, respectively). There is no recent congress trading data, and hedge funds and insiders remain neutral. Additionally, there are no strong event-driven catalysts or trading signals.
In Q4 2025, Septerna Inc reported a revenue increase of 11276.42% YoY to $24.12M. However, net income dropped by 48.05% to -$10.74M, and EPS fell by 61.90% to -0.24. Gross margin remained flat at 100%.
Analysts are optimistic, with JPMorgan, Truist, and H.C. Wainwright raising price targets to $38, $35, and $40, respectively, and maintaining Buy or Overweight ratings. This reflects confidence in the company's clinical trial progress and potential for SEP-631 approval.
